Abstract
The therapeutic effect of bifemerane hydrochloride (Celeport®) was studied in 42 patients with loss of the sense of smell caused by the common cold (group C) or head trauma (group T) who failed to respond to conventional treatment such as intranasal administration of betamethasone sodium phosphate. Celeport was administered in a daily dose 150mg tid or 100mg bid for 2 to 20 months. We assessed the effect of Celeport on the threshold of olfactory sensation and perception using the T & T olfactogram. The patients of group C showed significant improvement both in the threshold of olfactory sensation and perception after treatment. On the other hand, those of group T showed no significant recovery either in the threshold of olfactory sensation or perception. The rate of improvement in aged patients with loss of smell caused by the common cold was better than that in young patients. Therefore, we assumed that in aged patients the location of olfactory pathology caused by the common cold is not only the olfactory mucosa and nerve, but also the olfactory central nervous system.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
